Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Inclusion Criteria: * · Male or female \> 18 years of age * Diagnosis of open-angle glaucoma or ocular hypertension * IOP \> 16 mm Hg in each eye at the latanoprost -treated baseline evaluation * Presently on latanoprost monotherapy for at least 6 weeks * Ability to provide informed consent and likely to complete all study visits Exclusion Criteria: * · Known contraindication or allergy to brimonidine or any of its components * Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2% * Uncontrolled systemic disease * Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator. * Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed). * Corneal abnormalities * History of intraocular surgery within the last 3 months * Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control * Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.